US Stock MarketDetailed Quotes
ELVN Enliven Therapeutics
- 23.150
- +0.150+0.65%
Close Dec 13 16:00 ET
- 23.150
- 0.0000.00%
Post 16:00 ET
1.13BMarket Cap-12.84P/E (TTM)
23.710High22.610Low153.66KVolume23.190Open23.000Pre Close3.56MTurnover0.62%Turnover RatioLossP/E (Static)48.86MShares30.03052wk High3.92P/B575.59MFloat Cap10.90052wk Low--Dividend TTM24.86MShs Float250.840Historical High--Div YieldTTM4.78%Amplitude3.896Historical Low23.159Avg Price1Lot Size
About Enliven Therapeutics Company
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.
Company Profile
SymbolELVN
Company NameEnliven Therapeutics
Listing DateMar 12, 2020
Founded2019
CEOMr. Sam Kintz, M.B.A.
MarketNASDAQ
Employees46
Fiscal Year Ends12-31
Address6200 Lookout Road
CityBoulder
ProvinceColorado
CountryUnited States of America
Zip Code80301
Phone1-720-647-8519
Company Executives
- Name
- Position
- Salary
- Sam Kintz, M.B.A.
- President, Chief Executive Officer and Director
- 8.28M
- Benjamin Hohl
- Head of Corporate Development, Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Helen Collins, M.D.
- Chief Medical Officer
- 4.06M
- Dr. Anish Patel, Pharm.D.
- Chief Operating Officer
- --
- Dr. Richard Heyman, PhD
- Chairman of the Board
- 664.11K
- Dr. Lori Anne Kunkel, M.D.
- Director
- --
- Dr. Rahul D. Ballal, PhD
- Director
- 1.87M
- Jacob Bauer, M.B.A.
- Independent Director
- 551.21K
- Dr. Mika Derynck, M.D.
- Independent Director
- 541.48K
- Dr. Andrew Phillips, PhD
- Independent Director
- 542.95K
- Rishi Gupta, J.D.
- Independent Director
- 538.26K
Heat List
US
Overall
Symbol
Price
% Chg
No Data